High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
about
Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancerCancer of the endometrium: current aspects of diagnostics and treatmentGynecologic effects of tamoxifen and the association with endometrial carcinomaNovel piperidinedione analogs as inhibitors of breast cancer cell growth.MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer casesGenotoxicity of the some selective estrogen receptor modulators: a reviewHormonal pathology of the endometrium.CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.From adjuvant therapy to breast cancer prevention: BCPT and STAR.Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives.The effect of tamoxifen on the genital tractTamoxifen for prevention of breast cancer.Is there any association between uterine malignant mixed Mullerian tumour, breast cancer and prolonged tamoxifen treatment?Tumorigenic effects of tamoxifen on the female genital tract.Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repairThe effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.My approach to the interpretation of endometrial biopsies and curettings.Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.Endometrial adenocarcinoma: beliefs and scepticism.Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.Gynaecological effects of tamoxifen.Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.Secondary malignancies across the age spectrum.Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.Comparison of tamoxifen with danazol for treatment of cyclical mastalgia.Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats.Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma.Clear cell adenocarcinoma within a tamoxifen-related polyp.Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study.Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo.
P2860
Q24685693-1EA99525-0CD1-4A4A-BE5E-FFEDDDDA5ADFQ24797130-61FBEA9D-326E-44B4-9265-7D84BA0B9A52Q28284817-22091CD0-90E4-48CC-B327-C1DB0EAC4FC1Q31995278-58A2DB16-8EC9-407C-A261-CAA3F985543CQ33750187-FE51C9BF-D495-4B17-A548-86F9DA3BEFADQ33849496-B1C25A1D-E200-47C6-8B55-3EE893477D9CQ33886753-53D56CBF-0E1F-462B-99FC-401309C15888Q33919557-1CC9F092-4FD9-4045-9EE2-D0B237B366FEQ34317586-A312234C-2D53-43C7-983D-E4E509C44EC4Q34397284-DC461436-82B2-47C3-8948-18C1C2122E51Q34593808-0B80AD0A-DDC6-416F-93B5-107E08850F55Q35054272-FE68FE2C-8222-4F0C-A3D7-94E9B22426EFQ35173197-ED28D25A-6CA5-4BDF-904A-A5ECF021B703Q35176493-C8643EC8-CFCF-4201-9042-34A505851A07Q35251010-7C984AED-5621-4412-9CD6-909898A60F2AQ35586245-65E68DAB-1402-4432-BCAE-D80A40CA277DQ35659643-7D23B706-F289-437D-B23D-CE6A2137CEB5Q35770233-06CFAFD2-D805-48A3-BBA5-57E2AC121630Q35785095-1F1B2F28-16A8-43F3-9B99-8508FD7133C4Q35790406-4778ABC6-C7AB-4774-813C-7826AACD6CC8Q36274927-CAD8F68B-3165-4A6D-A7A0-85EC5C02662DQ36684234-0E3BE337-48A7-4686-B3BD-3AED00F25448Q37177723-5131D69F-2E52-404B-8696-595C850DCF90Q37230397-EDEE9A63-1133-431A-BF95-68473B9AC5C2Q37236376-DE9E5739-0968-4977-B382-6E16AB6B43AFQ37379773-35AB8BEA-C8FF-43F8-8679-E80E9B082454Q37392149-CC7F7D97-E996-48F7-8662-EA082DCADC9BQ39450663-F4B42E88-0036-47D2-99CE-65925195B0BAQ42542657-C76BA141-76F7-4A3B-9016-F7B8CB4C43B5Q42551786-9B2FF6EE-0085-4D1A-98CD-CABC74847F1CQ43906641-799DD33C-F629-4BDA-A73F-B42F1239A0FBQ44169398-634B9246-8FED-47BA-A384-FE5AA799408AQ50663926-AE805A29-E83A-4E77-B697-2A7B090A1AF5Q53424873-C8468E38-AD97-4E84-90CF-A027E6116404
P2860
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@en
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@nl
type
label
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@en
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@nl
prefLabel
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@en
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@nl
P2093
P1476
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
@en
P2093
F Naftolin
M L Carcangiu
P E Schwartz
U Magriples
P304
P356
10.1200/JCO.1993.11.3.485
P407
P577
1993-03-01T00:00:00Z